✕ Sensationalism [8/10]: The headline uses emotionally charged personal narrative ('My son has a terminal disease') to frame a policy critique, prioritizing emotional appeal over neutral presentation of the issue.

"My son has a terminal disease — why FDA delays are failing families like mine"

✕ Framing by Emphasis [7/10]: The headline emphasizes personal suffering over institutional or scientific context, setting a tone of moral urgency that may overshadow balanced policy discussion.

"My son has a terminal disease — why FDA delays are failing families like mine"

✕ Loaded Language [9/10]: Phrases like 'gilded office' and 'lost touch' cast FDA officials as detached and elitist, injecting moral judgment into a policy discussion.

"I asked Food & Drug Administration (FDA) Commissioner Dr. Martin Makary to leave his gilded office and come visit my home, because I fear that he’s lost touch with terminally ill children like Ryu."

✕ Appeal to Emotion [10/10]: The article repeatedly emphasizes the child’s suffering, dreams, and dependency to evoke sympathy, potentially at the expense of rational policy analysis.

"He always dreamed of being a Navy SEAL; now he just hopes to live long enough to cast his first ballot."

✕ Editorializing [9/10]: The author, writing in first person, presents opinions as moral truths, such as equating inaction with guaranteed death, without counterbalancing scientific or regulatory perspectives.

"What we need is a system that recognizes that doing nothing is a decision that is deadly, 100% of the time."

✕ Narrative Framing [8/10]: The story is structured as a moral tale — suffering family vs. bureaucratic indifference — which simplifies a complex regulatory process into a hero-villain dynamic.

"But our hopes were dashed over and over again as therapies were subjected to extended review cycles, accelerated approval pathways were ignored, and previously authorized treatments were paused, restricted, or effectively sidelined."

✕ Vague Attribution [8/10]: Claims about treatment delays and policy failures are attributed to the author’s personal experience without citing specific cases, data, or independent verification.

"therapies were subjected to extended review cycles, accelerated approval pathways were ignored"

✕ Omission [10/10]: No FDA officials, regulatory experts, or scientists are quoted to provide context on safety standards, trial requirements, or risk-benefit assessments.

✕ Cherry-Picking [7/10]: The article presents only the perspective of a single affected family and nonprofit aid for steroids, omitting broader stakeholder views such as patient advocacy groups with differing opinions or clinical researchers.

"My husband and I thankfully found a nonprofit that covered the remaining $2,000 after our insurance paid their portion — but other expenses fall squarely on us."

✕ Omission [10/10]: No information is provided on the specific experimental drugs sought, their clinical trial status, known risks, or why they may not yet be approved — essential context for evaluating the FDA’s decisions.

✕ Misleading Context [9/10]: The article implies that faster approval would directly save lives, but does not acknowledge potential risks of unproven therapies or historical cases where rushed approvals caused harm.

"Experimental drugs could let Ryu avoid their fate, but we can’t access them under a regulatory environment that appears to prioritize bureaucratic caution over the lives of dying children."

✕ Selective Coverage [7/10]: The focus on Dr. Prasad’s departure and the call for a 'reset' appears designed to pressure leadership change rather than inform on systemic regulatory challenges.

"The upcoming departure of FDA’s Director of the Center for Biologics Evaluation and Research, Dr. Vinay Prasad, the man Makary assigned to make these life-and-death decisions, creates an opportunity for a reset."